All ACAD Content

Acadia Pharmaceuticals Inc (ACAD) Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) FY 2026 Other Release

April 7, 20261 min read

Acadia Pharmaceuticals Inc (ACAD) Forum

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Forum

March 12, 20261 min read

Acadia Pharmaceuticals Inc (ACAD) Q4 2025 Earnings Call Transcript

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Q4 2025 Earnings Call dated Feb. 25, 2026 Corporate Participants: Al Kildani — Senior Vice...

March 10, 202648 min read

Acadia Pharmaceuticals Inc (ACAD) Sec Form 8K

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Sec Form 8K

March 6, 20261 min read

Acadia Pharmaceuticals Inc (ACAD) Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) FY 2026 Management Update

March 3, 20261 min read

Acadia Pharmaceuticals Inc (ACAD) Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) FY 2026 Other Release

March 2, 20261 min read

Acadia Pharmaceuticals Inc (ACAD) Sec Form 10K

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Sec Form 10K

February 28, 20261 min read

Acadia Pharmaceuticals Inc (ACAD) Sec Form 8K

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Sec Form 8K

February 27, 20261 min read

Acadia Pharmaceuticals Inc (ACAD) Earnings Release

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Q4 2025 Earnings Release

February 25, 20261 min read

Acadia Pharmaceuticals Inc (ACAD) Q4 2025 Earnings Call

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Q4 2025 Earnings Conference

February 25, 20261 min read